Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Feb:198:19-22.
doi: 10.1016/j.thromres.2020.11.020. Epub 2020 Nov 23.

Low molecular weight heparin and 28-day mortality among patients with coronavirus disease 2019: A cohort study in the early epidemic era

Wei Qin  1 , Fen Dong  2 , Zhu Zhang  3 , Bingzhu Hu  1 , Shi Chen  1 , Ziyang Zhu  1 , Fajiu Li  1 , Xiaojiang Wang  1 , Yunxia Zhang  3 , Yimin Wang  3 , Kaiyuan Zhen  3 , Jing Wang  4 , Ismaïl Elalamy  5 , Chenghong Li  6 , Zhenguo Zhai  7 , Bruce L Davidson  8 , Chen Wang  9
Affiliations
Observational Study

Low molecular weight heparin and 28-day mortality among patients with coronavirus disease 2019: A cohort study in the early epidemic era

Wei Qin et al. Thromb Res. 2021 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Factors associated with 28-day mortality in multivariable Cox regression analysis Note: X axis values were hazard ratios, log10-scale. §Underlying diseases included any of the following diseases: coronary disease, hypertension, diabetes, chronic respiratory diseases, chronic kid diseases. † The normal lower limit for lymphocyte count was 1.1 × 109/L, normal upper limits were 14 s for prothrombin time and 1 mg/L for D-dimer. ‡ In cox model, SOFA score at admission ≥3, LMWH use and immune globulin treatment during hospitalization violated proportional hazard assumption and their interactions with follow-up days were input in model (all Pinteraction < 0.01).
See this image and copyright information in PMC

References

    1. Connors J.M., Levy J.H. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135:2033–2040. - PMC - PubMed
    1. Li C., Hu B., Zhang Z. D-dimer triage for COVID-19. Acad. Emerg. Med. Off. J. Soc. Acad. Emerg. Med. 2020;27:612–613. - PMC - PubMed
    1. Ahmed S., Zimba O., Gasparyan A.Y. Thrombosis in coronavirus disease 2019 (COVID-19) through the prism of Virchow’s triad. Clin. Rheumatol. 2020;39:2529–2543. - PMC - PubMed
    1. Lederer D.J., Bell S.C., Branson R.D. Control of confounding and reporting of results in causal inference studies. Guidance for authors from editors of respiratory, sleep, and critical care journals. Ann. Am. Thorac. Soc. 2019;16:22–28. - PubMed
    1. Whyte C.S., Morrow G.B., Mitchell J.L. Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19. J. Thromb. Haemost. 2020;18:1548–1555. - PMC - PubMed

Substances